Instructions Sorbilact solution for infusions glass bottle 200 ml
Composition
active ingredients: 1 ml of solution contains sorbitol 200 mg; sodium lactate (calculated as 100% substance) 19 mg; sodium chloride 6 mg; calcium chloride dihydrate (calculated as calcium chloride) 0.1 mg; potassium chloride 0.3 mg; magnesium chloride hexahydrate (calculated as magnesium chloride) 0.2 mg;
excipient: water for injections.
Dosage form
Solution for infusion.
Main physical and chemical properties: transparent colorless liquid; theoretical osmolarity – 1658 mOsmol/l; pH 6.00-7.60; ionic composition: 1 l of the preparation contains Na+ – 272.20 mmol; K+ – 4.02 mmol; Ca++ – 0.90 mmol; Mg++ – 2.10 mmol; Cl- – 112.69 mmol; Lac- – 169.55 mmol.
Pharmacotherapeutic group
Solutions that affect electrolyte balance. Electrolytes in combination with other drugs. ATX code B05B B04.
Pharmacological properties
Pharmacodynamics
The drug has anti-shock, energetic, detoxifying, alkalizing, diuretic effects and stimulates intestinal peristalsis.
The main pharmacologically active substances of the drug are sorbitol (in hypertonic concentration) and sodium lactate (in isotonic concentration). Hypertonic sorbitol solution has a pronounced stimulating effect on intestinal smooth muscles. In the liver, sorbitol is first converted into fructose, which is subsequently converted into glucose, and then into glycogen. Part of sorbitol is used for immediate energy needs, the other part is stored as a reserve in the form of glycogen. Hypertonic sorbitol solution has a high osmotic pressure and a pronounced ability to enhance diuresis.
Unlike bicarbonate solution, correction of metabolic acidosis with sodium lactate proceeds more slowly as it is incorporated into the metabolism, and there are no sharp fluctuations in pH. The effect of sodium lactate becomes apparent 20-30 minutes after administration.
Sodium chloride – has a detoxifying, rehydrating effect, replenishes the deficiency of sodium and chlorine ions in various pathological conditions.
Calcium chloride replenishes the deficiency of calcium ions. Calcium ions are necessary for the transmission of nerve impulses, contraction of skeletal and smooth muscles, myocardial activity, bone formation, blood clotting. Reduces the permeability of cells and vascular walls, prevents the development of inflammatory reactions, increases the body's resistance to infections.
Potassium chloride restores water and electrolyte balance. Has a negative chrono- and bathmotropic effect, in high doses - a negative ino-, dromotropic and moderate diuretic effect. Participates in the process of conducting nerve impulses. Increases the content of acetylcholine and causes excitation of the sympathetic division of the autonomic nervous system. Improves skeletal muscle contraction in muscular dystrophy, myasthenia.
Pharmacokinetics
Sorbitol is quickly included in the general metabolism, 80-90% of it is utilized in the liver and accumulates in the form of glycogen, 5% is deposited in the brain tissues, cardiac muscle and skeletal muscles, 6-12% is excreted in the urine. When injected into the vascular bed, sodium, CO2 and H2O are released from sodium lactate, which form sodium bicarbonate, which leads to an increase in the alkaline reserve of the blood. Only half of the injected sodium lactate (isomer L) is considered active, and the other half (isomer D) is not metabolized and is excreted in the urine.
Sodium chloride is rapidly excreted from the vascular bed, only temporarily increasing the volume of circulating blood. It increases diuresis.
Indication
To reduce intoxication due to hyperosmolarity of the solution, improve microcirculation, correct acid-base status, improve hemodynamics in traumatic, surgical, hemolytic and burn shock; peritonitis and intestinal obstruction (in the pre- and postoperative period); acute renal failure of various etiologies; sepsis; cholecystitis; various liver diseases (hepatitis, liver dystrophy, hepatic coma); increased intracranial pressure in case of cerebral edema.
Contraindication
Individual hypersensitivity to the components of the drug. Sorbilact® should not be used in alkalosis, dehydration, as well as in cases where the infusion of large volumes of fluid is contraindicated (cerebral hemorrhage, thromboembolism, cardiovascular decompensation, arterial hypertension of the III degree, terminal renal failure, pulmonary edema, decompensated heart defects, anuria, oliguria).
Interaction with other medicinal products and other types of interactions
Do not use as a solvent carrier for other medicinal products.
Application features
The drug should be used under the control of indicators of acid-base status and blood electrolytes, functional state of the liver and blood pressure. Administer with caution to patients with calculous cholecystitis. The drug should be used taking into account the osmolarity of blood and urine, as well as acid-base status. Administration of Sorbilact to patients with diabetes mellitus should be carried out under the control of blood sugar content.
The drug contains sorbitol, so patients with rare hereditary fructose intolerance should not use this drug.
Use during pregnancy or breastfeeding
There is no data on contraindications during pregnancy or breastfeeding.
Ability to influence reaction speed when driving vehicles or other mechanisms
Since the drug should be used in a hospital setting, there is no data on such effects.
Method of administration and doses
Sorbilact® should be administered intravenously to adults by drip at a rate of 40-60 cc/min.
If necessary, the drug can be injected intravenously after the test by drip injection at a rate of 30 drops/min. After the injection of 15 drops, the drug should be discontinued, and after 3 minutes, if there is no reaction, Sorbilact® should be injected intravenously.
In traumatic, burn, postoperative and hemolytic shocks, adults should be administered 200-600 ml (3-10 ml/kg of body weight) once and 200-400 ml repeatedly, first as a jet, then as a drip. In liver diseases, adults should be administered 200 ml (3.5 ml/kg of body weight) drip daily or every other day.
In acute renal failure, adults should be administered a single dose of 200-400 ml (2.5-6.5 ml/kg of body weight) drip or jet (repeatedly after 8-12 hours in a dose of 200 ml).
For the prevention of postoperative intestinal paresis, adults should be administered in a single dose of 150-300 ml (2.5-5 ml/kg of body weight) drip; repeated infusions of 200 ml of the drug are possible every 12 hours during the first 2-3 days after surgery. For the treatment of postoperative paresis, adults should be administered in a dose of 200-400 ml (3.5-6.5 ml/kg of body weight) drip, every 8 hours until intestinal motility is normalized. In case of cerebral edema, adults should first be administered in a jet, and then drip (60-80 drops per minute) in a dose of 5-10 ml/kg of body weight. In case of significant dehydration, intravenous infusions of Sorbilact® should be carried out only drip (no more than 200 ml of solution per day).
Children
There is insufficient data on experience with use in children.
Overdose
There are phenomena of alkalosis, dehydration, which quickly disappear on their own, provided that the drug is immediately stopped. If the rate of administration is exceeded, tachycardia, increased blood pressure, shortness of breath, headache, abdominal pain may develop. These symptoms quickly disappear on their own after stopping or significantly reducing the rate of solution administration. If dehydration occurs, symptomatic therapy should be used.
Adverse reactions
On the part of the immune system: anaphylactoid reactions, angioedema, hyperthermia.
From the cardiovascular system: increase or decrease in blood pressure, tachycardia, shortness of breath, acrocyanosis.
Neurological disorders: tremor, headache, dizziness, general weakness.
Skin and subcutaneous tissue disorders: skin rash, urticaria, itching.
Gastrointestinal disorders: abdominal pain, nausea, vomiting.
General disorders: changes at the injection site, including pain and burning.
Alkalosis or dehydration (due to hyperosmolarity of the solution), collapse, dehydration (due to increased diuresis) may occur.
Expiration date
2 years.
Storage conditions
Store at a temperature not exceeding 25 ° C. Do not freeze. Keep out of the reach of children.
Incompatibility
Sorbilact® cannot be mixed with phosphate- and carbonate-containing solutions.
Do not use as a solvent carrier for other medicinal products.
Packaging
200 ml or 400 ml in a bottle, 1 bottle in a pack; 200 ml or 400 ml in bottles; 250 ml or 500 ml in containers.
Vacation category
According to the recipe.
Producer
LLC "Yuria-Pharm".
Location of the manufacturer and its business address
Ukraine, 18030, Cherkasy, Verbovetskogo St., 108.
